<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p237" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_237{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_237{left:306px;bottom:30px;}
#t3_237{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_237{left:346px;bottom:30px;}
#t5_237{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_237{left:517px;bottom:30px;}
#t7_237{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_237{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_237{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_237{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_237{left:35px;bottom:777px;letter-spacing:0.09px;word-spacing:0.09px;}
#tc_237{left:35px;bottom:759px;letter-spacing:0.06px;word-spacing:0.12px;}
#td_237{left:35px;bottom:739px;letter-spacing:0.16px;}
#te_237{left:405px;bottom:739px;}
#tf_237{left:35px;bottom:702px;letter-spacing:0.06px;word-spacing:0.13px;}
#tg_237{left:35px;bottom:683px;letter-spacing:0.03px;word-spacing:-0.2px;}
#th_237{left:35px;bottom:665px;letter-spacing:0.06px;word-spacing:0.12px;}
#ti_237{left:35px;bottom:645px;letter-spacing:0.16px;}
#tj_237{left:405px;bottom:645px;}
#tk_237{left:35px;bottom:608px;letter-spacing:-0.07px;word-spacing:0.27px;}
#tl_237{left:35px;bottom:589px;letter-spacing:0.03px;word-spacing:-0.62px;}
#tm_237{left:35px;bottom:570px;letter-spacing:0.04px;word-spacing:0.15px;}
#tn_237{left:35px;bottom:551px;letter-spacing:0.16px;}
#to_237{left:405px;bottom:551px;}
#tp_237{left:35px;bottom:514px;word-spacing:-0.48px;}
#tq_237{left:35px;bottom:495px;letter-spacing:0.1px;word-spacing:0.08px;}
#tr_237{left:35px;bottom:476px;letter-spacing:0.01px;word-spacing:0.18px;}
#ts_237{left:35px;bottom:457px;letter-spacing:0.07px;word-spacing:0.12px;}
#tt_237{left:35px;bottom:437px;letter-spacing:0.16px;}
#tu_237{left:405px;bottom:437px;}
#tv_237{left:35px;bottom:401px;letter-spacing:0.05px;word-spacing:0.13px;}
#tw_237{left:35px;bottom:382px;letter-spacing:-0.06px;word-spacing:0.25px;}
#tx_237{left:35px;bottom:363px;letter-spacing:0.15px;word-spacing:-0.11px;}
#ty_237{left:35px;bottom:343px;letter-spacing:-0.38px;}
#tz_237{left:59px;bottom:343px;letter-spacing:0.15px;}
#t10_237{left:418px;bottom:343px;}
#t11_237{left:35px;bottom:306px;letter-spacing:0.08px;word-spacing:-0.72px;}
#t12_237{left:35px;bottom:288px;letter-spacing:0.05px;word-spacing:0.13px;}
#t13_237{left:35px;bottom:269px;letter-spacing:0.02px;word-spacing:0.17px;}
#t14_237{left:35px;bottom:249px;letter-spacing:-0.1px;word-spacing:0.28px;}
#t15_237{left:170px;bottom:249px;letter-spacing:0.16px;}
#t16_237{left:530px;bottom:249px;}
#t17_237{left:35px;bottom:212px;letter-spacing:0.11px;word-spacing:0.07px;}
#t18_237{left:35px;bottom:194px;letter-spacing:0.09px;word-spacing:0.1px;}
#t19_237{left:35px;bottom:174px;letter-spacing:0.05px;word-spacing:-0.92px;}
#t1a_237{left:35px;bottom:155px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1b_237{left:35px;bottom:135px;letter-spacing:0.16px;}
#t1c_237{left:405px;bottom:135px;}
#t1d_237{left:35px;bottom:100px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1e_237{left:35px;bottom:80px;letter-spacing:0.05px;word-spacing:-0.89px;}
#t1f_237{left:35px;bottom:61px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1g_237{left:618px;bottom:777px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1h_237{left:618px;bottom:759px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1i_237{left:618px;bottom:739px;letter-spacing:0.16px;}
#t1j_237{left:979px;bottom:739px;}
#t1k_237{left:618px;bottom:702px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1l_237{left:618px;bottom:683px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1m_237{left:618px;bottom:665px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1n_237{left:618px;bottom:645px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1o_237{left:618px;bottom:625px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1p_237{left:618px;bottom:606px;letter-spacing:0.16px;}
#t1q_237{left:988px;bottom:606px;}
#t1r_237{left:618px;bottom:570px;letter-spacing:0.13px;word-spacing:-0.39px;}
#t1s_237{left:618px;bottom:551px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1t_237{left:618px;bottom:531px;letter-spacing:-0.02px;word-spacing:-0.68px;}
#t1u_237{left:618px;bottom:512px;letter-spacing:0.15px;word-spacing:-0.66px;}
#t1v_237{left:618px;bottom:492px;letter-spacing:-0.23px;word-spacing:1.63px;}
#t1w_237{left:715px;bottom:492px;letter-spacing:0.16px;}
#t1x_237{left:1076px;bottom:492px;}
#t1y_237{left:618px;bottom:457px;letter-spacing:0.02px;word-spacing:-0.73px;}
#t1z_237{left:618px;bottom:437px;letter-spacing:-0.01px;word-spacing:0.2px;}
#t20_237{left:618px;bottom:418px;letter-spacing:0.12px;word-spacing:0.07px;}
#t21_237{left:618px;bottom:398px;letter-spacing:0.16px;}
#t22_237{left:988px;bottom:398px;}
#t23_237{left:618px;bottom:363px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t24_237{left:618px;bottom:343px;letter-spacing:0.02px;word-spacing:0.16px;}
#t25_237{left:618px;bottom:324px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t26_237{left:618px;bottom:304px;letter-spacing:0.08px;word-spacing:0.1px;}
#t27_237{left:618px;bottom:284px;letter-spacing:0.16px;}
#t28_237{left:988px;bottom:284px;}
#t29_237{left:618px;bottom:249px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2a_237{left:618px;bottom:229px;letter-spacing:-0.02px;word-spacing:0.21px;}
#t2b_237{left:618px;bottom:210px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2c_237{left:618px;bottom:190px;letter-spacing:-0.23px;word-spacing:1.63px;}
#t2d_237{left:715px;bottom:190px;letter-spacing:0.16px;}
#t2e_237{left:1084px;bottom:190px;}
#t2f_237{left:618px;bottom:155px;letter-spacing:0.09px;word-spacing:-0.62px;}
#t2g_237{left:618px;bottom:135px;word-spacing:-1.05px;}
#t2h_237{left:618px;bottom:116px;letter-spacing:-0.03px;word-spacing:0.21px;}
#t2i_237{left:618px;bottom:96px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2j_237{left:618px;bottom:77px;letter-spacing:0.16px;}
#t2k_237{left:988px;bottom:77px;}
#t2l_237{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_237{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_237{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_237{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_237{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_237{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_237{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s6_237{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts237" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg237Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg237" style="-webkit-user-select: none;"><object width="1210" height="935" data="237/237.svg" type="image/svg+xml" id="pdf237" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_237" class="t s0_237">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_237" class="t s1_237">© </span>
<span id="t3_237" class="t s0_237">(NCCN </span>
<span id="t4_237" class="t s1_237">© </span>
<span id="t5_237" class="t s0_237">), All rights reserved. NCCN Guidelines </span>
<span id="t6_237" class="t s1_237">® </span>
<span id="t7_237" class="t s0_237">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_237" class="t s2_237">NCCN Guidelines Version 4.2024 </span>
<span id="t9_237" class="t s2_237">Head and Neck Cancers </span>
<span id="ta_237" class="t s3_237">MS-96 </span>
<span id="tb_237" class="t s4_237">high-risk patients for adjuvant chemotherapy: a randomized controlled </span>
<span id="tc_237" class="t s4_237">trial. J Clin Oncol 2018:JCO2018777847. Available at: </span>
<span id="td_237" class="t s5_237">https://www.ncbi.nlm.nih.gov/pubmed/29989858</span><span id="te_237" class="t s4_237">. </span>
<span id="tf_237" class="t s4_237">496. Liang Y, Li J, Li Q, et al. Plasma protein-based signature predicts </span>
<span id="tg_237" class="t s4_237">distant metastasis and induction chemotherapy benefit in nasopharyngeal </span>
<span id="th_237" class="t s4_237">carcinoma. Theranostics 2020;10:9767-9778. Available at: </span>
<span id="ti_237" class="t s5_237">https://www.ncbi.nlm.nih.gov/pubmed/32863958</span><span id="tj_237" class="t s4_237">. </span>
<span id="tk_237" class="t s4_237">497. Wang WY, Twu CW, Chen HH, et al. Plasma EBV DNA clearance </span>
<span id="tl_237" class="t s4_237">rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal </span>
<span id="tm_237" class="t s4_237">carcinoma. Clin Cancer Res 2010;16:1016-1024. Available at: </span>
<span id="tn_237" class="t s5_237">https://www.ncbi.nlm.nih.gov/pubmed/20103659</span><span id="to_237" class="t s4_237">. </span>
<span id="tp_237" class="t s4_237">498. Xu JY, Wei XL, Ren C, et al. Association of plasma Epstein-Barr virus </span>
<span id="tq_237" class="t s4_237">DNA with outcomes for patients with recurrent or metastatic </span>
<span id="tr_237" class="t s4_237">nasopharyngeal carcinoma receiving anti-programmed cell death 1 </span>
<span id="ts_237" class="t s4_237">immunotherapy. JAMA Netw Open 2022;5:e220587. Available at: </span>
<span id="tt_237" class="t s5_237">https://www.ncbi.nlm.nih.gov/pubmed/35230439</span><span id="tu_237" class="t s4_237">. </span>
<span id="tv_237" class="t s4_237">499. al-Sarraf M, Pajak TF, Cooper JS, et al. Chemo-radiotherapy in </span>
<span id="tw_237" class="t s4_237">patients with locally advanced nasopharyngeal carcinoma: a radiation </span>
<span id="tx_237" class="t s4_237">therapy oncology group study. J Clin Oncol 1990;8:1342-1351. Available </span>
<span id="ty_237" class="t s4_237">at: </span><span id="tz_237" class="t s5_237">https://www.ncbi.nlm.nih.gov/pubmed/2199621</span><span id="t10_237" class="t s4_237">. </span>
<span id="t11_237" class="t s4_237">500. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent </span>
<span id="t12_237" class="t s4_237">cisplatin-radiotherapy compared with radiotherapy alone in locoregionally </span>
<span id="t13_237" class="t s4_237">advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536- </span>
<span id="t14_237" class="t s4_237">539. Available at: </span><span id="t15_237" class="t s5_237">http://www.ncbi.nlm.nih.gov/pubmed/15812080</span><span id="t16_237" class="t s4_237">. </span>
<span id="t17_237" class="t s4_237">501. Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent </span>
<span id="t18_237" class="t s4_237">chemoradiotherapy versus radiotherapy alone for advanced </span>
<span id="t19_237" class="t s4_237">nasopharyngeal carcinoma: positive effect on overall and progression-free </span>
<span id="t1a_237" class="t s4_237">survival. J Clin Oncol 2003;21:631-637. Available at: </span>
<span id="t1b_237" class="t s5_237">https://www.ncbi.nlm.nih.gov/pubmed/12586799</span><span id="t1c_237" class="t s4_237">. </span>
<span id="t1d_237" class="t s4_237">502. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy </span>
<span id="t1e_237" class="t s4_237">versus concurrent chemoradiotherapy followed by adjuvant chemotherapy </span>
<span id="t1f_237" class="t s4_237">in patients with American Joint Committee on Cancer/International Union </span>
<span id="t1g_237" class="t s4_237">against cancer stage III and IV nasopharyngeal cancer of the endemic </span>
<span id="t1h_237" class="t s4_237">variety. J Clin Oncol 2005;23:6730-6738. Available at: </span>
<span id="t1i_237" class="t s5_237">http://www.ncbi.nlm.nih.gov/pubmed/16170180</span><span id="t1j_237" class="t s4_237">. </span>
<span id="t1k_237" class="t s4_237">503. Lee AWM, Tung SY, Ng WT, et al. A multicenter, phase 3, </span>
<span id="t1l_237" class="t s4_237">randomized trial of concurrent chemoradiotherapy plus adjuvant </span>
<span id="t1m_237" class="t s4_237">chemotherapy versus radiotherapy alone in patients with regionally </span>
<span id="t1n_237" class="t s4_237">advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and </span>
<span id="t1o_237" class="t s4_237">toxicity. Cancer 2017;123:4147-4157. Available at: </span>
<span id="t1p_237" class="t s5_237">https://www.ncbi.nlm.nih.gov/pubmed/28662313</span><span id="t1q_237" class="t s4_237">. </span>
<span id="t1r_237" class="t s4_237">504. Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus </span>
<span id="t1s_237" class="t s4_237">adjuvant chemotherapy versus concurrent chemoradiotherapy alone in </span>
<span id="t1t_237" class="t s4_237">patients with locoregionally advanced nasopharyngeal carcinoma: a phase </span>
<span id="t1u_237" class="t s4_237">3 multicentre randomised controlled trial. Lancet Oncol 2012;13:163-171. </span>
<span id="t1v_237" class="t s4_237">Available at: </span><span id="t1w_237" class="t s5_237">http://www.ncbi.nlm.nih.gov/pubmed/22154591</span><span id="t1x_237" class="t s4_237">. </span>
<span id="t1y_237" class="t s4_237">505. Wang S, Li S, Shen L. Combined chemoradiation vs radiation therapy </span>
<span id="t1z_237" class="t s4_237">alone in stage-II nasopharyngeal carcinoma: A meta-analysis of the </span>
<span id="t20_237" class="t s4_237">published literature. Curr Probl Cancer 2018;42:302-318. Available at: </span>
<span id="t21_237" class="t s5_237">https://www.ncbi.nlm.nih.gov/pubmed/29759802</span><span id="t22_237" class="t s4_237">. </span>
<span id="t23_237" class="t s4_237">506. Liu F, Jin T, Liu L, et al. The role of concurrent chemotherapy for </span>
<span id="t24_237" class="t s4_237">stage II nasopharyngeal carcinoma in the intensity-modulated </span>
<span id="t25_237" class="t s4_237">radiotherapy era: a systematic review and meta-analysis. PLoS One </span>
<span id="t26_237" class="t s4_237">2018;13:e0194733. Available at: </span>
<span id="t27_237" class="t s5_237">https://www.ncbi.nlm.nih.gov/pubmed/29566078</span><span id="t28_237" class="t s4_237">. </span>
<span id="t29_237" class="t s4_237">507. Xu C, Zhang LH, Chen YP, et al. Chemoradiotherapy versus </span>
<span id="t2a_237" class="t s4_237">radiotherapy alone in stage II nasopharyngeal carcinoma: a systemic </span>
<span id="t2b_237" class="t s4_237">review and meta-analysis of 2138 patients. J Cancer 2017;8:287-297. </span>
<span id="t2c_237" class="t s4_237">Available at: </span><span id="t2d_237" class="t s5_237">https://www.ncbi.nlm.nih.gov/pubmed/28243333</span><span id="t2e_237" class="t s4_237">. </span>
<span id="t2f_237" class="t s4_237">508. Huang X, Chen X, Zhao C, et al. Adding concurrent chemotherapy to </span>
<span id="t2g_237" class="t s4_237">intensity-modulated radiotherapy does not improve treatment outcomes for </span>
<span id="t2h_237" class="t s4_237">stage II nasopharyngeal carcinoma: a phase 2 multicenter clinical trial. </span>
<span id="t2i_237" class="t s4_237">Front Oncol 2020;10:1314. Available at: </span>
<span id="t2j_237" class="t s5_237">https://www.ncbi.nlm.nih.gov/pubmed/32850414</span><span id="t2k_237" class="t s4_237">. </span>
<span id="t2l_237" class="t s6_237">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
